Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
SUTRO BIOPHARMA, INC. (STRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/10/2023 8-K Quarterly results
Docs: "Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Session at ESMO 2023 - - Sutro announced a royalty monetization agreement with Blackstone Life Sciences in June 2023, under which Sutro received an upfront payment of $140 million, and is eligible to receive up to an additional $250 million in milestone payments upon the achievement of certain return thresholds - - As of June 30, 2023, Sutro had cash and investments of $358.3 million and shares ..."
05/15/2023 8-K Quarterly results
Docs: "Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 - - As presented at AACR 2023, STRO-003 demonstrated potent anti-tumor activity and immune-modulating properties in preclinical models, suggesting its potential to augment checkpoint blockade therapy - - As of March 31, 2023, Sutro had cash and investments of $251.5 million and shares of Vaxcyte common stock valued at $25.0 million, which together provide a projected cash runway into the second half of 2024-"
04/27/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
02/24/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Section 1.1: Annual Meetings If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date and time as the Board of Directors of Sutro Biopharma, Inc. shall each year fix. The meeting may be held either at a place, within or without the State of Delaware as permitted by the Delaware General Corporation Law , or by means of remote communication as the Board in its sole discretion may determine. Any proper business may be transacted at the annual meeting. Section 1.2: Special Meetings Special meetings of stockholders for any purpose or purposes shall be called in the manner set forth in the Restated Certificate of Incorporation of the Corporation . The special meeting may be held either at a place, within or without the State of Del..."
01/09/2023 8-K Investor presentation
Docs: "2.5 2.3 2.4 2.6 2.3 2.5 2.5",
"Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin , Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer - Results from the STRO-002 Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg - - Meaningful clinical benefit was observed in FolRα-selected patients, defined as TPS>25%, which is potentially 80% of the advanced ovarian cancer patient population - - Safety profile is generally consistent with prior data with asymptomatic neutropenia being the primary adverse event; no new safety signals were observed - - Use of prophylactic pegfilgrastim reduced dose delays ...",
"2.5 2.3 2.4 2.6 2.3 2.5 2.5"
12/20/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
07/26/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
Docs: "Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones - Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023 - - Meetings with regulatory agencies for STRO-002 are planned for mid-year 2022 and near-final dose expansion data are expected in the second half of 2022 - - First patient was dosed in the STRO-002 bevacizumab combination trial and the endometrial cohort continues to enroll patients - SOUTH SAN FRANCISCO, Calif., May 9, 2022 – Sutro Biopharma, Inc. , a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer t..."
04/20/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
02/28/2022 8-K Quarterly results
Docs: "Sutro Biopharma, Inc. Selected Statements of Operations Financial Data"
01/10/2022 8-K Investor presentation
Docs: "2 3 4 3"
01/05/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact",
"33 PR 3 4 7 PR"
12/27/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
11/17/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/10/2021 8-K Investor presentation, Quarterly results
Docs: "Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones",
"Company Overview Presentation"
10/12/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
09/30/2021 8-K Other Events  Interactive Data
08/09/2021 8-K Quarterly results
06/17/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/19/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
04/15/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
12/09/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"Opinion of Fenwick & West LLP"
12/07/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting - STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached -"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy